DSIP
A 1970s sleep-and-stress peptide whose human evidence stayed sparse and inconsistent for half a century.
Verdict — C · Emerging / Mixed
A long-standing sleep peptide that never accumulated the evidence to match its longevity — sparse, inconsistent human data and an under-characterised mechanism. No major safety signal, but a C: for the experienced, on thin evidence and unverified supply.
Overview
Delta-sleep-inducing peptide (DSIP) was isolated by Schoenenberger and Monnier in the 1970s and named for its proposed sleep-promoting activity. Despite decades of availability, the human evidence base remained small and inconsistent, with unclear pharmacokinetics and a mechanism that is still poorly characterised. It is used in the gray market as a sleep and anti-stress aid. There is no major documented safety signal, but the absence of robust modern trials and verified sourcing keeps it firmly mid-pack.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.